$VXRT *Vaxart to advance three oral tablet COVID-19 vaccine candidates to the clinic: VXA-CoV2-1 (includes both the S and the N proteins) into Phase II and two S-only constructs into Phase I/II Four clinical trials of the oral norovirus vaccine candidate to be initiated in 2021 Cash, cash equivalents, and marketable securities of $177.3 million as of March 31, 2021 Today 8k filed to SEC looks pretty nice.
3
14
14 Likes